FREE TO REGISTER - PARTNERING OPEN NOW UNTIL MAY 21!

ACCESS CONTENT LIVE MAY 4-6 & PANEL PLAYBACK UNTIL JULY 30.

REGISTER

WHY ATTEND CANCER PROGRESS?

Jeff Bockman explains the importance of attending Cancer Progress 2021 and participating in partnering in his video below. Check it out to get a clearer picture of what to expect at Cancer Progress 2021.

VIDEO

Thanks to the generosity of our sponsors, we are now offering complimentary registration! In lieu of a registration fee, we ask that you kindly consider donating to help fund cancer-related and COVID-19-related charitable organizations so that we may exceed the more than $20,000 we donated in 2020. Click the button below to donate. Thank you for your generosity and support!

DONATE

CATCH THIS PANEL AT CANCER PROGRESS 2021:

"Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors"

DAY ONE: MAY 4, 2021
10:15-11:30 AM

CO-MODERATOR:
Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting

CO-MODERATOR:
James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting

Joined by Esteemed Panelists:
Neil Brewis, PhD, CSO, F-star Therapeutics
Michael A. Curran, PhD, Associate Professor, Dept. of Immunology, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Founder, ImmunoGenesis, Inc.
Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
Laurent Levy, PhD, CEO, Nanobiotix
Michael J. Newman, PhD, President & CEO, Decoy Biosystems, Inc.
Thomas Schuetz, MD, PhD, CEO and Co-founder, Compass Therapeutics
Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early, Development, Merck and Co.
Mai-Britt Zocca, PhD, Founder & CEO, IO Biotech

The above panel will focus on perhaps the most active area of drug development in Oncology: the effort to improve upon outcomes with checkpoint inhibitors (CPI) by combining agents post failure of the checkpoint with the CPI to resensitize the tumor microenvironment and enable patients to continue to derive benefit from immunotherapies. A diverse array of MOAs and therapeutic approaches are being harnessed to try to address this daunting task, ranging from new checkpoint inhibitors, costims and multifunctional biologics, to agents targeting other “bad actors’ and pathways in the TME including modulators of innate immunity. In addition, oncolytic viruses, agents driving immunogenic cell death, cancer vaccines and cell therapies are also looking to provide value in this checkpoint-experienced space. Finally, an alternative approach, but one requiring more wherewithal (financially and in time) is to bring such new agents forward into combination with checkpoint right at the start, into upfront settings.

Check Out the Full Agenda

Cancer Progress by Cello Health
25-B Hanover Road, Suite 320
Florham Park, NJ 07932
Eileen Tuma, Conference Organizer
cellohealthbioconsulting.com | cancerprogressbycellohealth.com | cellohealth.com

linkedin twitter

Unsubscribe